This suggested that PGM5 downregulation may affect disease progression and prognosis in prostate cancer patients by influencing cell cycle, DNA repair and multiple oncologic pathways, which could be further explored and confirmed in future analysis. This evidence concerns the gene PGM5 and prostate cancer.